Your browser doesn't support javascript.
loading
Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study.
Xu, Jianming; Shen, Lin; Zhou, Zhiwei; Li, Jie; Bai, Chunmei; Chi, Yihebali; Li, Zhiping; Xu, Nong; Li, Enxiao; Liu, Tianshu; Bai, Yuxian; Yuan, Ying; Li, Xingya; Wang, Xiuwen; Chen, Jia; Ying, Jieer; Yu, Xianjun; Qin, Shukui; Yuan, Xianglin; Zhang, Tao; Deng, Yanhong; Xiu, Dianrong; Cheng, Ying; Tao, Min; Jia, Ru; Wang, Wei; Li, Jing; Fan, Songhua; Peng, Mengye; Su, Weiguo.
Affiliation
  • Xu J; Department of Gastrointestinal Oncology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China. Electronic address: jmxu2003@yahoo.com.
  • Shen L; Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
  • Zhou Z; Department of Gastric Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Li J; Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
  • Bai C; Department of Medical Oncology, Peking Union Medical College Hospital, Beijing, China.
  • Chi Y; National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Li Z; Department of Abdominal Oncology, West China Hospital, Sichuan University, Chengdu, China.
  • Xu N; Department of Medical Oncology, The First Affiliated Hospital of Zhejiang University, Hangzhou, China.
  • Li E; Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  • Liu T; Department of Medical Oncology, Zhongshan Hospital of Fudan University, Shanghai, China.
  • Bai Y; Department of Gastrointestinal Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Yuan Y; Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Li X; Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Wang X; Department of Medical Oncology, Qilu Hospital of Shandong University, Jinan, China.
  • Chen J; Department of Oncology, Jiangsu Cancer Hospital, Nanjing, China.
  • Ying J; Department of Abdominal Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
  • Yu X; Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Qin S; People's Liberation Army Cancer Center of Nanjing Jinling Hospital, Nanjing, China.
  • Yuan X; Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Zhang T; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Deng Y; Department of Medical Oncology, The Sixth Affiliated Hospital, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases l, Sun Yat-sen University, Guangzhou, Guangdong, China.
  • Xiu D; Department of General Surgery, Peking University Third Hospital, Beijing, China.
  • Cheng Y; Department of Thoracic Oncology, Jilin Provincial Cancer Hospital, Changchun, China.
  • Tao M; Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Jia R; Department of Gastrointestinal Oncology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China.
  • Wang W; Department of Gastric Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Li J; Department of Clinical Development and Regulatory Affairs, Hutchison MediPharma, Shanghai, China.
  • Fan S; Department of Clinical Development and Regulatory Affairs, Hutchison MediPharma, Shanghai, China.
  • Peng M; Department of Clinical Development and Regulatory Affairs, Hutchison MediPharma, Shanghai, China.
  • Su W; Department of Clinical Development and Regulatory Affairs, Hutchison MediPharma, Shanghai, China.
Lancet Oncol ; 21(11): 1500-1512, 2020 11.
Article in En | MEDLINE | ID: mdl-32966811
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / Neuroendocrine Tumors / Angiogenesis Inhibitors / Drug-Related Side Effects and Adverse Reactions Type of study: Clinical_trials / Prognostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2020 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / Neuroendocrine Tumors / Angiogenesis Inhibitors / Drug-Related Side Effects and Adverse Reactions Type of study: Clinical_trials / Prognostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2020 Type: Article